Qiagen's HC2 More Effective Than Pap Test In Preventing Cancer - Study
Qiagen/Digene's Hybrid Capture 2 human papillomavirus (HPV) DNA test is more effective than Pap testing alone in preventing cervical cancer, according to the results of a large-scale study published online Jan. 19 in The Lancet Oncology
More from Archive
More from Medtech Insight
Thena Capital, the first UK-based early-stage specialist medtech firm, has made its first investment since closing its £50m fund. Medtech Insight spoke with general partner Pamela Walker Geddes to gain insight into Thena Capital’s investment strategy.
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.